DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study on Amino Acid Uptake in Brain Tumors

Information source: University Hospital Muenster
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Brain Neoplasms

Intervention: O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: University Hospital Muenster

Official(s) and/or principal investigator(s):
Matthias Weckesser, MD, Principal Investigator, Affiliation: Department of Nuclear Medicine, University Hospital Muenster


The purpose of this study is to determine the uptake of the amino acid O-(2-[F-18]Fluorethyl)-L-tyrosin (FET) in human brain tumors using positron emission tomography. A comparison to MRI and histopathological samples is used.

Clinical Details

Official title: Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Primary outcome:

Histological samples where available

CD98 staining where available

Secondary outcome: Clinical follow-up for at least one year

Detailed description: Radioactively labelled amino acids have been used for years to delineate primary brain tumors and for the early detection of tumor recurrence. Positron emission tomography studies indicate that the extent of amino acid uptake correlates to the true histological extent of gliomas. Recently a fluorine-18 labelled amino acid has been introduced (O-(2-[F-18]Fluorethyl)-L-tyrosin (FET)), which is suitable for routine use in brain tumor patients. There is evidence that this amino acid is transported into brain and brain tumors by the amino acid transport of the L-type. The cDNA of this L-transporter has recently been cloned and has been shown to be identical to the light chain of the 4F2-antigen (CD98), which has previously been described as marker of cell growth and proliferation. The heavy chain of this heterodimer is known to modulate integrins which are thought to play a fundamental role in glioma invasion. Besides the evaluation of the diagnostic capability of FET in brain tumors, a comparison of FET uptake in vivo and CD98 expression ex-vivo is performed with tissue slices as available after routine surgery in glioma patients.


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients with suspected primary brain tumors

- CT or MRI showing lesion of >= 2,5 cm

- Any age; parents informed consent in children available

- Karnofsky-Index >= 20 %

- Referral by Depts. of Neurology, Neuro-Oncology, Neurosurgery, or Pediatric Neurology

at the UKM

- Biopsy and/or surgery planned

- Patient is able to lie during the PET scan for 50 minutes without moving • Patient

must be able to give informed consent; signature must be present before the PET scan Exclusion Criteria:

- Pregnancy or breast feeing

- Patients, who by psychiatric disease are not able to give informed consent

- Complete renal failure

- Inclusion to other studies according to § 23 of the German radiation protection law

Locations and Contacts

Department of Nuclear Medicine, University Hospital Muenster, Muenster, NRW D-48149, Germany
Additional Information

Starting date: January 2004
Last updated: September 13, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017